Ménard S, Squicciarini P, Luini A, Sacchini V, Rovini D, Tagliabue E, Veronesi P, Salvadori B, Veronesi U, Colnaghi M I
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Br J Cancer. 1994 Jun;69(6):1126-9. doi: 10.1038/bjc.1994.221.
Methods such as immunohistochemistry that have enhanced the detection of carcinoma cells in bone marrow aspirates appear to be useful in identifying patients with aggressive tumours. To detect epithelial cells in bone marrow aspirates from breast carcinoma patients, we used a pool of five different monoclonal antibodies (MAbs), which recognise 100% of breast carcinomas, together with the alkaline phosphatase method on cytospun cells obtained from sternum and iliac crest. Primary tumours were also analysed for the expression of the c-erbB-1 and c-erbB-2 oncogene products, and of two differentiation-related markers and laminin receptors. Immunoreactive cells were detected in the bone marrow of 62 of the 197 patients tested (31%) without any correlation with clinical parameters such as tumour size or lymph node metastasis, whereas a significant (P < 0.01) correlation was found with enhanced monomeric laminin receptor expression in the primary tumour. In fact, this receptor was expressed in respectively 63% and 38% of primary tumours from patients with and without immunoreactive cells in the bone marrow aspirates. Thus, the presence of immunoreactive cells in bone marrow correlates with the expression in the primary tumour of a marker of the metastatic potential of the tumour, the 67 kDa laminin receptor.
诸如免疫组织化学等方法提高了骨髓穿刺液中癌细胞的检测能力,似乎有助于识别患有侵袭性肿瘤的患者。为了检测乳腺癌患者骨髓穿刺液中的上皮细胞,我们使用了一组五种不同的单克隆抗体(MAb),这些抗体可识别100%的乳腺癌,同时结合碱性磷酸酶法对取自胸骨和髂嵴的细胞涂片进行检测。还对原发性肿瘤进行了c-erbB-1和c-erbB-2癌基因产物以及两种分化相关标志物和层粘连蛋白受体表达的分析。在197例接受检测的患者中,有62例(31%)的骨髓中检测到免疫反应性细胞,这与肿瘤大小或淋巴结转移等临床参数无任何相关性,而与原发性肿瘤中单体层粘连蛋白受体表达增强存在显著(P<0.01)相关性。事实上,在骨髓穿刺液中有和没有免疫反应性细胞的患者的原发性肿瘤中,该受体的表达分别为63%和38%。因此,骨髓中免疫反应性细胞的存在与肿瘤转移潜能标志物67 kDa层粘连蛋白受体在原发性肿瘤中的表达相关。